Diallo Dapa, Tchernia Gil
Hematology Laboratory, Faculty of Medicine, Pharmacy and Odontostomatology, Bamako, Mali.
Curr Opin Hematol. 2002 Mar;9(2):111-6. doi: 10.1097/00062752-200203000-00005.
Africa is the main birthplace of sickle mutations; the number of newborns affected by sickle cell disease is estimated at 200,000 per year. However, because of low family income and public health funding and, to a lesser extent, because of local beliefs about sickle cell disease, overall treatment of patients is still poor and, in some places, inadequate. Efforts to adapt therapeutic options and overcome difficulties are presented and analyzed.
非洲是镰状细胞突变的主要发源地;据估计,每年受镰状细胞病影响的新生儿数量为20万。然而,由于家庭收入和公共卫生资金水平较低,以及在较小程度上由于当地对镰状细胞病的认知,患者的总体治疗情况仍然较差,在一些地方甚至不足。本文介绍并分析了调整治疗方案和克服困难的努力。